Company: TYRA
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0000950170-25-046124
Chunk: 167

Company: Tyra Biosciences, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1B
Chunk 167
---
 to the development of any of our product candidates could significantly change the costs and timing associated with the development of that product candidate. 

The process of conducting the necessary preclinical and clinical research to obtain regulatory approval is costly and time-consuming. The actual probability of success for our product candidates or any future candidates may be affected by a variety of factors. We may never succeed in achieving regulatory approval for any of our product candidates or any future candidates. 

General and Administrative Expenses 

General and administrative expenses consist primarily of personnel-related expenses, including employee salaries, bonuses, benefits, and stock-based compensation charges for personnel in executive, finance and other administrative functions. Other significant general and administrative expenses include legal fees relating to intellectual property and corporate matters, allocated facility-related costs, professional fees for accounting, tax, business development and consulting services and insurance costs. We expect our general and administrative expenses will increase for the foreseeable future to support our increased research and development activities, manufacturing activities, and the increased costs associated with operating as a public company. These increased costs will likely include increased expenses related to hiring additional personnel, audit, legal, regulatory and tax-related services associated with maintaining compliance with exchange listing and the Securities and Exchange Commission (SEC) requirements, director and officer insurance costs, and investor and public relations costs. 

Other Income

Other income consist primarily of interest income from cash, cash equivalents and marketable securities and accretion income from marketable securities.

Results of Operations for the Years Ended December 31, 2024 and 2023

The following table summarizes our results of operations for the periods indicated (in thousands):

    Year Ended December 31,

    2024

    2023

    Change

    Operating expenses:

    Research and development
     
    $
    80,077

    $
    62,518

    $
    17,559

    General and administrative

    24,100

    17,427

    6,673

    Total operating expenses

    104,177

    79,945

    24,232

    Loss from operations

    (104,177
    )

    (79,945
    )

    (24,232
    )

    Other income:

    Interest and other income, net

    17,696

    10,811

    6,885

    Total other income

    17,696

    10,811

    6,885

    Net loss